| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,149 |
1,117 |
$64K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
298 |
291 |
$27K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
422 |
415 |
$21K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
423 |
416 |
$10K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
209 |
206 |
$7K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
61 |
61 |
$5K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
60 |
60 |
$2K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
113 |
111 |
$1K |
| S0302 |
Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) |
133 |
133 |
$1K |
| 96127 |
|
53 |
50 |
$682.96 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
37 |
36 |
$447.47 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
13 |
13 |
$412.21 |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
26 |
26 |
$337.37 |
| 94760 |
|
160 |
154 |
$292.50 |